Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume 6

eBook: US $79 Special Offer (PDF + Printed Copy): US $134
Printed Copy: US $95
Library License: US $316
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-981-14-7841-3 (Print)
ISBN: 978-981-14-7843-7 (Online)
Year of Publication: 2021
DOI: 10.2174/97898114784371200601

Introduction

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers.

The sixth volume of the book features reviews on these topics:

- Immunomodulating Agents in The Treatment of Acute Myeloid Leukemia

- Potential Natural Products for Prostate Cancer Management

- Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design

- Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) For Advanced Hepatocellular Carcinoma

- Targeting Cancer Stem Cells: Implications in Health and Disease

Preface

Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments in various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students, and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research.

The five chapters in this volume are written by eminent authorities in the field. Chapter 1 deals with the role of the PI3K/AKT/mTOR pathway in the survival of malignant cells as a potential target to combat relapse in AML patients. It also covers therapeutic agents involving a new class of inhibitors for plausible approaches to treat patients with relapsed or refractory AML diseases. Chapter 2 discusses the role of some natural products as potential novel anti-tumor agents treat CRPC patients. Chapter 3 presents an overview of key proteins and their coordinating and/or cooperating partner proteins in protein pathways which can be useful to design innovative chemotherapeutics. Chapter 4 deals with the effectiveness of Hepatic Arterial Infusion Chemotherapy (HAIC) for advanced hepatocellular carcinoma. Chapter 5 summarizes the current strategies and discusses lead molecules which have found their way to preclinical and clinical studies for targeting cancer stem cells.


I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel therapies against cancers.

I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications) and Mrs. Salma Sarfaraz (Senior Manager Publications) at Bentham Science Publishers.


Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

RELATED BOOKS

.Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach.
.The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach.
.Cancer Medicine in an Ayurvedic Perspective: A Critical Overview.
.Cancer Genes.